SCHEMBL1311061

SCHEMBL1311061

Nc1ccc(NC(=O)Nc2cccc([N+](=O)[O-])c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.79
▸ KMT2A Q03164 8/20 0.79
▸ MAPT P10636 6/20 0.79
▸ HTT P42858 5/20 0.79
▸ POLB P06746 3/20 0.79
▸ DDX3X O00571 2/20 0.79
▸ CTDSP1 Q9GZU7 1/20 0.79
▸ CA12 O43570 2/20 0.73
▸ CA1 P00915 2/20 0.73
▸ CA2 P00918 2/20 0.73
▸ CA9 Q16790 2/20 0.73
▸ CA5A P35218 1/20 0.73
▸ CA5B Q9Y2D0 1/20 0.73
▸ GAA P10253 2/20 0.72
▸ BAZ1A Q9NRL2 4/20 0.69
▸ TP53 P04637 1/20 0.64
▸ CASP3 P42574 1/20 0.64
▸ NPSR1 Q6W5P4 1/20 0.64
▸ SENP7 Q9BQF6 1/20 0.64
▸ NPC1 O15118 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL20268307 0.99 MEN1 (0.77) MEN1KMT2AMAPTHTTPOLB
SCHEMBL1047211 0.89 MEN1 (1.00) MEN1KMT2AMAPTHTTPOLB
SCHEMBL6129390 0.88 MEN1 (0.90) MEN1KMT2AMAPTHTTPOLB
SCHEMBL17084065 0.88 MEN1 (0.96) MEN1KMT2AMAPTHTTPOLB
SCHEMBL6819562 0.87 KMT2A (0.72) MEN1KMT2AMAPTHTTPOLB
SCHEMBL29494979 0.85 CNR1 (0.85) MEN1KMT2AMAPTHTTPOLB
SCHEMBL22092552 0.85 MEN1 (0.79) MEN1KMT2AMAPTHTTPOLB
SCHEMBL29494985 0.85 MEN1 (0.79) MEN1KMT2AMAPTHTTPOLB
SCHEMBL22092547 0.85 MEN1 (0.79) MEN1KMT2AMAPTHTTPOLB
SCHEMBL22092548 0.85 CNR1 (0.85) MEN1KMT2AMAPTHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555189-B1 REPAIRABLE POLYMER COMPOSITIONS KINECTRICS UK LTD (GB) 2022-03-16 — — EP disclosed
US-20110275635-A1 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT THE UAB RESEARCH FOUNDATION (US) 2011-11-10 — — US disclosed
US-20110275635-A1 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT THE UAB RESEARCH FOUNDATION (US) 2011-11-10 — — US disclosed
WO-2010123591-A2 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT THE UAB RESEARCH FOUNDATION (US) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275635-A1 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT NAMPT, NAPRT, NNT MEN1 889/4885KMT2A 1419/4885MAPT 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback